Suprane Liquid
NDC Package 10019-641-34

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Suprane (desflurane) liquids is the use of SUPRANE is contraindicated in the following conditions:•Known or suspected genetic susceptibility to malignant hyperthermia.•Patients in whom general anesthesia is contraindicated.•Induction of anesthesia in pediatric patients.•Patients with known sensitivity to SUPRANE or to other halogenated agents [See Warnings and Precautions (5.5)].•Patients with a history of moderate to severe hepatic dysfunction following anesthesia with SUPRANE or other halogenated agents and not otherwise explained [See Warnings and Precautions (5.5)]. This formulation utilizes a liquid delivery system. Marketed by Baxter Healthcare Corporation, this product is identified by NDC 10019-641 and is authorized under FDA application NDA020118.

Identification & Billing

NDC Package Code
10019-641-34
Package Description
6 BOTTLE in 1 CARTON / 240 mL in 1 BOTTLE (10019-641-64)
Product Code
10019-641
11-Digit Billing Format
10019064134
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Suprane
Non-Proprietary Name
Desflurane
Substance Name
Desflurane
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Administration Route
Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Active Ingredient(s)
DESFLURANE 240 mL/240mL
Pharmacologic Class
Usage Information
The use of SUPRANE is contraindicated in the following conditions:•Known or suspected genetic susceptibility to malignant hyperthermia.•Patients in whom general anesthesia is contraindicated.•Induction of anesthesia in pediatric patients.•Patients with known sensitivity to SUPRANE or to other halogenated agents [See Warnings and Precautions (5.5)].•Patients with a history of moderate to severe hepatic dysfunction following anesthesia with SUPRANE or other halogenated agents and not otherwise explained [See Warnings and Precautions (5.5)].

Regulatory & Marketing

Labeler Name
Baxter Healthcare Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA020118
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-18-1992
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (10019-641). Click a package code to view its specific billing and regulatory data.

10019-641-24
6 BOTTLE, GLASS in 1 CARTON / 240 mL in 1 BOTTLE, GLASS (10019-641-60)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10019-641-34 identifies a specific commercial package of 6 bottle in 1 carton / 240 ml in 1 bottle (10019-641-64) of Suprane, a human prescription drug labeled by Baxter Healthcare Corporation. This liquid is formulated for respiratory (inhalation) use and contains desflurane as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Baxter Healthcare Corporation on September 18, 1992. The current certification is valid through December 31, 2027.

How is this Baxter Healthcare Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10019064134. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10019-641-34
11-Digit CMS (5-4-2)
10019-0641-34

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.